Successfully prepare & profit from the 12th hike

Post a Comment

The Fed has increased interest rates eleven times since March 2022.

Each time, traders following our recommendations had the opportunity to lock in 75% profits in the next trading session thanks to high-volume trades by large institutions.

If you missed out, you have a short window to prepare and profit from what my research convinces me will be a 12th hike during the next FOMC meeting (October 31st – Nov. 1).

Here's some material to work with ahead of your next trading session…


The Next Wealth Transfer in Biotech
Begins as "Blockbuster Patents" Expire

Patents are often the engines behind biotech investments that make you rich.

So understandably, pharmaceutical companies — including Pfizer, Johnson & Johnson, Novo Nordisk, and more — have a stash of over $700 billion for new mergers and acquisitions to cover expiring patents for blockbuster drugs (like AbbVie's Humira).

But unlike the 2020 boom when speculation drove valuations, the best-performing biotech investments over the next ten years will be companies that show "positive proof-of-concept" that the drug or platform they're developing works as promised.

These ones have the biggest potential for investors and the easiest way to profit is by piggybacking on insider-purchasing activities ahead of mergers or FDA approvals.




Call us: (888) 233-8598

DISCLAIMER: * Futures, stocks, and spot currency trading have large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures, stocks, and forex markets. Don't trade with money you can't afford to lose. This website is neither a solicitation nor an offer to Buy/Sell futures, stocks or forex. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this website. Past performance of indicators or methodology are not necessarily indicative of future results.

CFTC Regulation 4.41 These results are based on simulated or hypothetical performance results that have certain inherent limitations. Unlike the results shown in an actual performance record, these results do not represent actual trading. Also, because these trades have not actually been executed, these results may have under-or over-compensated for the impact, if any, of certain market factors, such as lack of liquidity. Simulated or hypothetical trading programs in general are also subject to the fact that they are designed with the benefit of hindsight. No representation is being made that any account will or is likely to achieve profits or losses similar to these being shown.

We'll always treat your personal information with the utmost care and will never sell it to third parties. You can find out more about what data we hold about you, why we need it, and how we keep that information safe in our Privacy Policy.

Related Posts

There is no other posts in this category.

Post a Comment

Subscribe Our Newsletter